Neuronetics (FRA:NRC) Moat Score: 4/10 (As of Jul. 05, 2026)


FRA:NRC Neuronetics Inc FRA:NRC
57 GF Score
Price €1.20
GF Value €1.65
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Neuronetics Moat Score?

Neuronetics FRA:NRC +2.58% 57 Moat Score is 4 as of Jul. 05, 2026. GuruFocus rates FRA:NRC with a GF Score™ of 57/100 and a GF Value™ of €1.65 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 845 Medical Devices & Instruments companies, Neuronetics ranks better than 83.31% on this metric.

Neuronetics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Neuronetics has Narrow Moat: Neuronetics Inc has a discernible but modest moat, primarily due to its intellectual property in medical devices. However, its market share and brand strength are limited, and it faces significant competition, preventing a higher moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Neuronetics might have Narrow Moat - Discernible but modest moat.

Neuronetics  (FRA:NRC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Neuronetics Moat Score Related Terms

FRA:NRC vs ZOMDF, OM, RPID: Moat Score Comparison

For the Medical Devices subindustry, Neuronetics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's Moat Score distribution charts can be found below:

* The bar in red indicates where Neuronetics's Moat Score falls into.


FRA:NRC
57GF Score
Neuronetics Inc FRA:NRC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Neuronetics (FRA:NRC) has a Moat Score of 4 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Neuronetics ranks #141 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Neuronetics' Moat Score too high?
Neuronetics' current Moat Score is 4. Based on the distribution chart, Neuronetics ranks #141 out of 845 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Neuronetics has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Moat Score compare to ZOMDF and OM?
According to the Medical Devices & Instruments industry distribution chart, Neuronetics ranks #141 out of 845 companies for Moat Score. This places Neuronetics in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Neuronetics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.65, compared to a current price of €1.20 — trading 27.6% below its estimated fair value. The current Moat Score is 4. Neuronetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Moat Score is 4 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.20 is trading 27.6% below its estimated GF Value™ of €1.65. GuruFocus considers Neuronetics to be Modestly Undervalued.

Key valuation signals for FRA:NRC:

  • Moat Score: 4
  • GF Value™: €1.65 vs. price of €1.20 (27.6% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
57GF Score

Get the complete analysis for FRA:NRC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.20
Price
€1.65
GF Value